Diabetic macular edema and proliferative diabetic retinopathy treated with anti-vascular endothelial growth factor under the reimbursement policy in Taiwan

The purpose of this retrospective interventional case series is to compare the functional and anatomical outcomes in eyes with diabetic macular edema (DME) and proliferative diabetic retinopathy (PDR) treated intravitreally with aflibercept or ranibizumab under the Taiwan National Insurance Bureau r...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Scientific reports 2022-01, Vol.12 (1), p.711-711, Article 711
Hauptverfasser:	Hsieh, Ming-Chieh, Cheng, Chieh-Yin, Li, Kun-Hsien, Chuang, Chih-Chun, Wu, Jian-Sheng, Lee, Sheng-Ta, Lu, Wei-Yang, Chiu, Shin-Lin, Liu, Yu-Ling, Chen, San-Ni
Format:	Artikel
Sprache:	eng
Schlagworte:	692/163/2743/137 692/163/2743/137/138 692/699/3161/3175 Aged Angiography Diabetes Diabetes Complications Diabetes mellitus Diabetic retinopathy Diabetic Retinopathy - diagnostic imaging Diabetic Retinopathy - therapy Edema Female Fluorescein Humanities and Social Sciences Humans Injection Insurance, Health, Reimbursement Laser Coagulation Lasers Light Coagulation Macular Edema - diagnostic imaging Macular Edema - etiology Macular Edema - therapy Male Middle Aged multidisciplinary Multivariate analysis National Health Programs Prognosis Ranibizumab - administration & dosage Ranibizumab - therapeutic use Receptors, Vascular Endothelial Growth Factor - administration & dosage Receptors, Vascular Endothelial Growth Factor - therapeutic use Recombinant Fusion Proteins - administration & dosage Recombinant Fusion Proteins - therapeutic use Reimbursement Retinopathy Retrospective Studies Science Science (multidisciplinary) Taiwan Time Factors Treatment Outcome Vascular endothelial growth factor
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The purpose of this retrospective interventional case series is to compare the functional and anatomical outcomes in eyes with diabetic macular edema (DME) and proliferative diabetic retinopathy (PDR) treated intravitreally with aflibercept or ranibizumab under the Taiwan National Insurance Bureau reimbursement policy. 84 eyes were collected and all eyes were imaged with spectral-domain optical coherence tomography (SD-OCT), color fundus photographs (CFPs), and fluorescein angiography (FA). At 24 months after therapy initiation, the logMAR BCVA improved from 0.58 ± 0.33 to 0.47 ± 0.38 ( p
ISSN:	2045-2322 2045-2322
DOI:	10.1038/s41598-021-04593-x